These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 32671728)
1. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy. Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553 [TBL] [Abstract][Full Text] [Related]
3. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654 [TBL] [Abstract][Full Text] [Related]
4. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834 [TBL] [Abstract][Full Text] [Related]
5. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155 [TBL] [Abstract][Full Text] [Related]
6. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. Gulati S; Desai J; Palackdharry SM; Morris JC; Zhu Z; Jandarov R; Riaz MK; Takiar V; Mierzwa M; Gutkind JS; Molinolo A; Desai PB; Sadraei NH; Wise-Draper TM Cancer; 2020 Jan; 126(2):354-362. PubMed ID: 31626727 [TBL] [Abstract][Full Text] [Related]
7. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Maguire PD; Neal CR; Hardy SM; Schreiber AM Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770 [TBL] [Abstract][Full Text] [Related]
8. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959 [TBL] [Abstract][Full Text] [Related]
9. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study]. Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226 [TBL] [Abstract][Full Text] [Related]
10. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696 [TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475 [TBL] [Abstract][Full Text] [Related]
12. Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin. Weykamp F; Seidensaal K; Rieken S; Green K; Mende S; Zaoui K; Freier K; Adeberg S; Debus J; Welte SE Strahlenther Onkol; 2020 Jun; 196(6):515-521. PubMed ID: 31784802 [TBL] [Abstract][Full Text] [Related]
13. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887 [TBL] [Abstract][Full Text] [Related]
14. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Rishi A; Rollins M; Ahmed KA; Hunt DC; Sarkar P; Fernandez DC; Hoffman MS; Apte SM; Shahzad MMK; Chon HS; Chern JY; Wenham RM; Montejo ME Gynecol Oncol; 2020 Feb; 156(2):349-356. PubMed ID: 31771865 [TBL] [Abstract][Full Text] [Related]
15. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes. Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921 [TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341 [TBL] [Abstract][Full Text] [Related]
18. [Concurrent simultaneous integrated boost radiotherapy and cetuximab in head and neck squamous cell cancer patients: is it feasible in daily clinical practice?]. Chillari F; Parisi S; Ferrantelli G; Carrubba C; Santacaterina A; Critelli P; Sciacca M; Venuti V; Lillo S; Cacciola A; Iatì G; Pontoriero A; Platania A; Delia P; Tombolini V; De Felice F; Musio D; Spatola C; Brogna A; Pergolizzi S Recenti Prog Med; 2024 May; 115(5):1e-6e. PubMed ID: 38708539 [TBL] [Abstract][Full Text] [Related]
19. A comparative study of the treatment outcome of moderately accelerated radiation fractionation (with concurrent chemotherapy in daily dosing) to conventional chemo-radiotherapy in locally advanced head and neck cancers: Supportive in a resource constrained environment. Arora C; Sharma N; Kapoor A; Pandya TN Indian J Cancer; 2024 Apr; 61(2):262-272. PubMed ID: 38090961 [TBL] [Abstract][Full Text] [Related]
20. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck. Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]